Haleos Labs Ltd

Haleos Labs Ltd

Haleos Labs Ltd has conducted a postal ballot for seeking approval of its shareholders for three resolutions. Resolutions 1, 3, and 4 have been passed with the requisite majority, while Resolution 2 did not receive the requisite majority and was not approved. The company has disclosed the voting results as required under Regulation 44(3) of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.

Haleos Labs Ltd

Haleos Labs Ltd has announced the outcome of its postal ballot, where resolutions 1, 3, and 4 were passed with the requisite majority, while resolution 2 regarding managerial remuneration to executive directors was not approved.

Haleos Labs Ltd

Haleos Labs Ltd has announced that it will deduct tax at source (TDS) on the final dividend declared for FY 2025-26, as per the Income Tax Act 2025. The company has sent an email to shareholders explaining the process of withholding tax and requesting them to update their PAN, address, category, and residential status with the Depositories or the Company's Registrar and Transfer Agent.

Haleos Labs Ltd

Haleos Labs Ltd has published its Q1FY27 results in newspapers as per SEBI regulations.

Haleos Labs Ltd

Haleos Labs Ltd's material subsidiary, Mahi Drugs Private Limited, has appointed Annapragada & Co. as its cost auditors for the year 2026-27 and Mr. Vincent P. Asrao as its nominee director.

Haleos Labs Ltd

Haleos Labs Ltd has announced the reappointment of Dr. Mannam Malakondaiah and Dr. Srinivas Samavedam as Independent Directors for a second term of 5 years, subject to shareholder approval.

Haleos Labs Ltd

Haleos Labs Ltd announced unaudited standalone and consolidated financial results for Q1 FY2027, with revenue from operations at Rs. 6,782.97 lakhs and net profit at Rs. 323.78 lakhs. The company also announced the re-appointment of two independent directors for a second term, revision of managerial remuneration, and holding of the 20th Annual General Meeting through video conferencing.

Haleos Labs Ltd

Haleos Labs Ltd has scheduled its 98th Board Meeting on August 5, 2026, to consider unaudited financial results for the quarter ended June 30, 2026, and other items.

Haleos Labs Ltd

Haleos Labs Ltd has announced a postal ballot and remote e-voting process for the reappointment of a whole-time director, managerial remuneration, material related party transactions, and other resolutions.

Haleos Labs Ltd

Haleos Labs Ltd has initiated a postal ballot for shareholder approval of four resolutions, including the reappointment of a whole-time director, payment of managerial remuneration to executive directors, and approval of material related party transactions.

Haleos Labs Ltd

Haleos Labs Ltd has announced an events calendar for a postal ballot to seek shareholder approval for resolutions related to the reappointment of a director, managerial remuneration, and related party transactions.